Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors

Hao‐Yue Xiang, Xiang Wang, Yanhong Chen, Xi Zhang, Cun Tan, Yi Wang, Yi Su, Zhiwei Gao, Xiaoyan Chen, Bing Xiong, Zhaobing Gao, Yi Chen, Jian Ding, Linghua Meng, Chunhao Yang